ArticleBMC cancer2026
Radiomics-based intratumoral heterogeneity subtypes in IDH wild-type glioblastoma with pathomic and transcriptomic association analyses: a multicenter study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIDH wild-type glioblastoma (IDH-wt GBM) exhibits substantial intratumoral heterogeneity, which contributes to treatment resistance, disease recurrence, and variable clinical outcomes. This study aimed to identify radiomics-based intratumoral heterogeneity (RITH) subtypes in IDH-wt GBM and to assess their prognostic relevance, associated pathomic differences, and transcriptomic associations.
methodsWe enrolled 333 patients with IDH-wt GBM across three cohorts. Radiomic features were extracted from CE-T1 and T2-FLAIR images, and partitioning around medoids (PAM) clustering was applied to identify RITH subtypes. Survival analyses included Kaplan-Meier analysis, log-rank tests, and univariable and multivariable Cox proportional hazards regression. Pathomic features extracted via CellProfiler were used to construct the PathScore to assess RITH subtype-associated pathomic differences. RNA-seq data from Cohort 3 were used for exploratory transcriptomic analysis, including candidate differentially expressed gene (DEG) identification, protein-protein interaction (PPI) network construction, and enrichment analysis.
resultsPAM clustering identified two RITH subtypes with significantly different overall survival (OS). The High RITH subtype was associated with shorter OS and remained independently associated with worse OS after adjustment for age, sex, hospital, MGMT promoter methylation status, and treatment category. The PathScore differed significantly between RITH subtypes, indicating associated histopathological differences. Exploratory transcriptomic analysis identified eleven candidate hub genes (CCL4, IL6, CSF2, HGF, IFNG, SERPINE1, CCR2, CXCR3, CXCL13, CCL20, and IL1B). Enrichment analyses suggested that these candidate hub genes were mainly associated with immune-inflammatory processes and pathways.
conclusionsThe High RITH subtype was associated with poorer survival and showed corresponding pathomic and exploratory transcriptomic associations. These findings suggest that RITH subtypes may serve as non-invasive imaging phenotypes linked to prognosis and biological heterogeneity in IDH-wt GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.